1. Home
  2. INDP vs CPHI Comparison

INDP vs CPHI Comparison

Compare INDP & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INDP
  • CPHI
  • Stock Information
  • Founded
  • INDP 2000
  • CPHI N/A
  • Country
  • INDP United States
  • CPHI China
  • Employees
  • INDP N/A
  • CPHI 231
  • Industry
  • INDP Biotechnology: Pharmaceutical Preparations
  • CPHI Biotechnology: Pharmaceutical Preparations
  • Sector
  • INDP Health Care
  • CPHI Health Care
  • Exchange
  • INDP Nasdaq
  • CPHI Nasdaq
  • Market Cap
  • INDP 6.0M
  • CPHI 5.3M
  • IPO Year
  • INDP N/A
  • CPHI N/A
  • Fundamental
  • Price
  • INDP $7.30
  • CPHI $1.64
  • Analyst Decision
  • INDP Strong Buy
  • CPHI
  • Analyst Count
  • INDP 2
  • CPHI 0
  • Target Price
  • INDP $238.00
  • CPHI N/A
  • AVG Volume (30 Days)
  • INDP 24.5K
  • CPHI 85.1K
  • Earning Date
  • INDP 08-11-2025
  • CPHI 08-13-2025
  • Dividend Yield
  • INDP N/A
  • CPHI N/A
  • EPS Growth
  • INDP N/A
  • CPHI N/A
  • EPS
  • INDP N/A
  • CPHI N/A
  • Revenue
  • INDP N/A
  • CPHI $4,295,377.00
  • Revenue This Year
  • INDP N/A
  • CPHI N/A
  • Revenue Next Year
  • INDP N/A
  • CPHI N/A
  • P/E Ratio
  • INDP N/A
  • CPHI N/A
  • Revenue Growth
  • INDP N/A
  • CPHI N/A
  • 52 Week Low
  • INDP $7.30
  • CPHI $1.20
  • 52 Week High
  • INDP $59.36
  • CPHI $3.35
  • Technical
  • Relative Strength Index (RSI)
  • INDP 31.62
  • CPHI 41.41
  • Support Level
  • INDP $8.00
  • CPHI $1.77
  • Resistance Level
  • INDP $10.57
  • CPHI $1.93
  • Average True Range (ATR)
  • INDP 0.79
  • CPHI 0.13
  • MACD
  • INDP -0.43
  • CPHI -0.02
  • Stochastic Oscillator
  • INDP 0.00
  • CPHI 21.62

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

About CPHI China Pharma Holdings Inc.

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.

Share on Social Networks: